Bazedoxifene: a guide to its use in postmenopausal osteoporosis.
Oral bazedoxifene (Conbriza®) reduces the incidence of new vertebral fractures in patients with postmenopausal osteoporosis. It also appears to reduce the risk of nonvertebral fractures in high-risk patients. Bazedoxifene is generally well tolerated and does not appear to have detrimental effects on endometrial or breast tissue.